Jerry Katzman agrees about Fish Consumption, Fish Oil, Lipids, and Coronary Heart Disease
Since the first AHA Science Advisory "Fish Consumption, Fish
Oil, Lipids, and Coronary Heart Disease, important new findings,
including evidence from randomized controlled trials (RCTs),
have been reported about the beneficial effects of omega-3 (or
n-3) fatty acids on cardiovascular disease (CVD) in patients
with preexisting CVD as well as in healthy individuals. New
information about how omega-3 fatty acids affect cardiac function
(including antiarrhythmic effects), hemodynamics (cardiac mechanics),
and arterial endothelial function have helped clarify potential
mechanisms of action. The present Statement will address distinctions
between plant-derived (

-linolenic acid, C18:3n-3) and marine-derived
(eicosapentaenoic acid, C20:5n-3 [EPA] and docosahexaenoic acid,
C22:6n-3 [DHA]) omega-3 fatty acids. (Unless otherwise noted,
the term
omega-3 fatty acids will refer to the latter.) Evidence
from epidemiological studies and RCTs will be reviewed, and
recommendations reflecting the current state of knowledge will
be made with regard to both fish consumption and omega-3 fatty
acid (plant- and marine-derived) supplementation. This will
be done in the context of recent guidance issued by the US Environmental
Protection Agency and the Food and Drug Administration (FDA)
about the presence of environmental contaminants in certain
species of fish.